Should drug makers be banned from buying back stock? Take our reader poll

A new analysis finds many drug makers spent more on buying back stock and paying dividends than on research and development.

Drug makers often argue that innovation would suffer whenever they are attacked for high prices. But a new analysis finds many of these companies have actually spent more on buying

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readPolitics
China Reports Sharp Rise In Cases Of Novel Virus Amid Growing Concerns Of Person-to-person Transmission
The number of cases of a novel virus in China has escalated sharply, with authorities in the city of Wuhan now reporting nearly 200 people infected, an increase of 136…
STAT3 min readWellness
WHO Raises Possibility Of ‘Sustained’ Human-to-human Transmission Of New Virus In China
The WHO raised the possibility that the new virus spreading in parts of China may be transmitting in an ongoing, sustained manner between people — which, if confirmed, would mark…
STAT4 min read
Opinion: We Don’t Need To Ban Vaping. We Need To Build Better Vaping Devices
We don't need to ban vaping. What we need to do is the research needed to build a better vape.